

Haematologica  
HAEMATOL/2016/151266  
Version 4

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Maximilian Merz, Hans Salwender, Mathias Haenel, Elias K. Mai, Uta Bertsch, Christina Kunz, Thomas Hielscher, Igor W. Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Jens Hillengass, Marc S. Raab, Baerbel Schurich, Markus Munder, Peter Brossart, Christian Gerecke, Hans-Walter Lindemann, Matthias Zeis, Katja Weisel, Jan Duerig, and Hartmut Goldschmidt

Disclosures: The GMMG MM5 Trial (EudraCT no. 2010-019173-16) is supported by grants from Janssen-Cilag, Celgene, Chugai and The Binding Site. Dr. Bertsch reports grants and other contributions from Janssen-Cilag as well as grants and other contributions from Celgene and grants from Chugai during the conduct of the study. Dr. Blau has nothing to disclose. Dr. Brossart has nothing to disclose. Dr. Dürig reports Honoraria and Consultancy fees provided by Janssen Cilag, and Honoraria from Celgene. Dr. Gerecke has nothing to disclose. Dr. Goldschmidt reports grants, personal fees and other from Janssen, grants, personal fees and other from Celgene, grants, personal fees and other from Novartis, grants and personal fees from Chugai, personal fees and other from Onyx, personal fees and other from Millennium, grants and other from BMS outside the submitted work. Dr. Hähnel has nothing to disclose. Dr. Hielscher has nothing to disclose. Dr. Hillengass reports other contributions from Celgene and from Janssen as well as from Medtronic outside the submitted work. Dr. Hose reports grants from Sanofi-Aventis, grants from EngMab AG, personal fees from Celgene, outside the submitted work.; Dr. Jauch has nothing to disclose. Dr. Kunz has nothing to disclose. Dr. Lindemann has nothing to disclose. Dr. Mai reports other contributions from Janssen-Cilag, Onyx, Celgene and from Mundipharma during the conduct of the study. Dr. Merz reports other contributions from Janssen, and Celgene during the conduct of the study. Dr. Munder reports personal fees from Bristol-Myers Squibb outside the submitted work. Dr. Raab has nothing to disclose. Dr. Salwender reports personal fees from Celgene, from Janssen Cilag and Binding site outside the submitted work. Dr. Scheid reports honoraria from Janssen, Celgene and Novartis outside the submitted work. Dr. Schurich has nothing to disclose. Dr. Seckinger has nothing to disclose. Dr. Weisel reports personal fees and non-financial support from Celgene and grants, personal fees and non-financial support from Janssen during the conduct of the study as well as personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Celgene, personal fees from Noxxon, personal fees and non-financial support from BMS, personal fees and non-financial support from Onyx, personal fees and non-financial support from AMGEN outside the submitted work. Dr. Zeis has nothing to disclose.